STOCK TITAN
  1. Home
  2. News
  3. SDGR

Schrodinger, Inc. - SDGR STOCK NEWS

Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.

Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.

Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.

Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.

Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.

Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.

News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to purchase 1,800 shares of the company’s common stock and restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. The stock options have an exercise price of $31.37 per share, a ten-year term, and vest over four years. The RSUs also vest over four years, with 25 percent vesting after 12 months of continuous service and the balance vesting in successive installments. These grants were made as a material inducement to the employees’ acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
-
News

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event

Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) presents data on SGR-1505's Phase 1 study, expansion of portfolio with EGFRC797S, PRMT5-MTA, and NLRP3 programs, and development efforts targeting synthetic lethality and DNA-damage repair mechanisms. The company also outlines anticipated milestones and provides a detailed review of its proprietary drug discovery and development programs during its Pipeline Day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.09%
Tags
none
-
News

Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, at the American Society of Hematology 65th Annual Meeting. Both candidates show favorable attributes and potential for combination activity with standard-of-care agents. The company also reported preliminary pharmacodynamic data from the Phase 1 study of SGR-1505 in healthy subjects. SGR-1505 and SGR-2921 are now being evaluated in Phase 1 clinical studies for B-cell malignancy and acute myeloid leukemia or myelodysplastic syndrome, respectively. The presentation at ASH demonstrated the potency of SGR-1505 and SGR-2921, with SGR-1505 showing greater modulation of NF-ΚΒ and related pathway genes compared to JNJ-6633, and SGR-2921 exhibiting significant anti-leukemic responses in patient-derived AML models. Schrödinger will provide additional data from the healthy subject study at its Pipeline Day on December 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) Grants Stock Options and Restricted Stock Units to Newly Hired Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
News

Schrödinger to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) announced its participation in two upcoming conferences in November. The company will have a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023, at 9:30 a.m. GMT, and a fireside discussion at the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023, at 9:30 a.m. ET. The discussions can be accessed on Schrödinger's website and will be archived for approximately seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
-
News

Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) announced that new data on its investigational MALT1 inhibitor, SGR-1505, and CDC7 inhibitor, SGR-2921, will be presented at the ASH 65th Annual Meeting. The data support the continued development of SGR-1505 as a potential therapy for advanced B-cell malignancies. Additionally, SGR-2921 demonstrates strong anti-leukemic activity in preclinical models of AML. Schrödinger will review these data as part of its Pipeline Day on December 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.69%
Tags
conferences
News

Schrödinger Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) reported total revenue of $42.6 million for the third quarter of 2023. The company maintains its full-year 2023 revenue guidance. Progress was made for SGR-1505, with healthy volunteer data expected in the fourth quarter of 2023. Phase 1 study was initiated for SGR-2921. Schrödinger also disclosed the PRMT5-MTA Discovery Program. BMS returned two programs from collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.69%
Tags
earnings
-
News

Schrödinger to Host Pipeline Day on December 14, 2023

Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) will host its Pipeline Day in New York City on December 14, 2023. The event will feature a detailed review of the company's development programs, including updates on SGR-1505, SGR-2921, SGR-3515, and multiple proprietary discovery programs. It will be a hybrid event with limited in-person attendance and a simultaneous webcast for virtual participation. The live presentation can be accessed on Schrödinger's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Schrödinger, Inc. has granted non-statutory stock options and restricted stock units (RSUs) to newly hired employees as part of their employment compensation. The stock options have an exercise price of $24.61 per share and a ten-year term, vesting over four years. The RSUs also vest over four years, with 25 percent vesting after 12 months of continuous service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
News

Schrödinger to Announce Third Quarter 2023 Financial Results on November 1

Rhea-AI Summary
Schrödinger to report Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
earnings

FAQ

What is the current stock price of Schrodinger (SDGR)?

The current stock price of Schrodinger (SDGR) is $20.84 as of November 22, 2024.

What is the market cap of Schrodinger (SDGR)?

The market cap of Schrodinger (SDGR) is approximately 1.5B.

What does Schrodinger, Inc. do?

Schrodinger, Inc. provides advanced molecular simulations and enterprise software solutions for pharmaceutical, biotechnology, and materials science research.

When was Schrodinger, Inc. founded?

Schrodinger, Inc. was founded in 1990.

What are the main segments of Schrodinger’s business?

Schrodinger operates through two main segments: Software and Drug Discovery.

How does Schrodinger generate revenue?

Schrodinger generates revenue from software sales, research funding, and milestone payments from drug discovery collaborations.

What industries does Schrodinger’s software cater to?

Schrodinger’s software caters to the life sciences industry and materials science industries.

What are some of Schrodinger’s recent achievements?

Schrodinger has made significant advancements in scientific research, enhancing drug discovery processes and establishing impactful partnerships in various fields.

Where are Schrodinger’s operations located?

Schrodinger has operations in the U.S., Europe, Japan, and India.

What is Nimbus Therapeutics?

Nimbus Therapeutics is a biotech company co-founded by Schrodinger, focusing on innovative drug discovery.

How has Schrodinger contributed to scientific research?

Schrodinger's researchers have contributed hundreds of peer-reviewed publications, often significantly cited in their fields.

What makes Schrodinger's software unique?

Schrodinger's software provides predictive power that accelerates research and development, reduces costs, and enables groundbreaking discoveries in drug discovery and materials science.

Stock SDGR logo
Schrodinger, Inc.

Nasdaq:SDGR

SDGR Rankings

#2232 Ranked by Market Cap
N/A Ranked by Dividends

SDGR Stock Data

1.51B
62.15M
2.39%
96.24%
12.22%
Health Information Services
Pharmaceutical Preparations
Link
United States of America
NEW YORK